{
  "guideline": {
    "id": "PA166127636",
    "name": "Annotation of CPIC Guideline for paroxetine and CYP2D6",
    "source": "CPIC",
    "version": 50,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166127636",
    "relatedChemicals": [
      {
        "id": "PA450801",
        "name": "paroxetine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298347",
      "name": "Recommendation PA166298347",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093851,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300883",
      "name": "Recommendation PA166300883",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093843,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298343",
      "name": "Recommendation PA166298343",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093847,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298356",
      "name": "Recommendation PA166298356",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093860,
        "html": "<p>Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298351",
      "name": "Recommendation PA166298351",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093855,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298342",
      "name": "Recommendation PA166298342",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093846,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166300884",
      "name": "Recommendation PA166300884",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093849,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "2.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298348",
      "name": "Recommendation PA166298348",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093852,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298344",
      "name": "Recommendation PA166298344",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093848,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298357",
      "name": "Recommendation PA166298357",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093861,
        "html": "<p>Consider a 50% reduction in recommended starting dose, slower titration schedule, and a 50% lower maintenance dose as compared to normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Greatly reduced metabolism when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects. The impact of paroxetine-associated autoinhibition of CYP2D6 is minimal in poor metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298352",
      "name": "Recommendation PA166298352",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093856,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301327",
      "name": "Recommendation Annotation PA166301327",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095646,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298349",
      "name": "Recommendation PA166298349",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093853,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298314",
      "name": "Recommendation PA166298314",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093844,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298358",
      "name": "Recommendation PA166298358",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093862,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298353",
      "name": "Recommendation PA166298353",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093857,
        "html": "<p>Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298073",
      "name": "Recommendation PA166298073",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093841,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298355",
      "name": "Recommendation PA166298355",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093859,
        "html": "<p>Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298346",
      "name": "Recommendation PA166298346",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093850,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298231",
      "name": "Recommendation PA166298231",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093842,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298341",
      "name": "Recommendation PA166298341",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093845,
        "html": "<p>Select alternative drug not predominantly metabolized by CYP2D6.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Increased metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers. Lower plasma concentrations decrease the probability of clinical benefit. The extent to which ultrarapid metabolizers phenoconvert to normal, intermediate, or poor metabolizers due to paroxetine autoinhibition of CYP2D6 is unclear."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298354",
      "name": "Recommendation PA166298354",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093858,
        "html": "<p>Consider a lower starting dose and slower titration schedule as compared to normal metabolizers.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when adjusting dose or selecting an alternative therapy.</p>\n"
      },
      "implications": [
        "CYP2D6: Reduced metabolism of paroxetine to less active compounds when compared to CYP2D6 normal metabolizers when starting treatment or at lower doses. Higher plasma concentrations may increase the probability of side\neffects. Paroxetine-associated phenoconversion of intermediate metabolizers to poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298350",
      "name": "Recommendation PA166298350",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450801",
          "name": "paroxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452093854,
        "html": "<p>Initiate therapy with recommended starting dose</p>\n"
      },
      "implications": [
        "CYP2D6: Normal metabolism of paroxetine to less active compounds. Paroxetine-associated phenoconversion of normal metabolizers to intermediate or poor metabolizers due to CYP2D6 autoinhibition may occur and is dose-dependent and greater at steady state concentrations."
      ],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "37032427",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.",
      "authors": [
        "Bousman Chad A",
        "Stevenson James M",
        "Ramsey Laura B",
        "Sangkuhl Katrin",
        "Hicks J Kevin",
        "Strawn Jeffrey R",
        "Singh Ajeet B",
        "Ruaño Gualberto",
        "Mueller Daniel J",
        "Tsermpini Evangelia Eirini",
        "Brown Jacob T",
        "Bell Gillian C",
        "Leeder J Steven",
        "Gaedigk Andrea",
        "Scott Stuart A",
        "Klein Teri E",
        "Caudle Kelly E",
        "Bishop Jeffrey R"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2023,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37032427"
    },
    {
      "pmid": "25974703",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.",
      "authors": [
        "Hicks J K",
        "Bishop J R",
        "Sangkuhl K",
        "Müller D J",
        "Ji Y",
        "Leckband S G",
        "Leeder J S",
        "Graham R L",
        "Chiulli D L",
        "LLerena A",
        "Skaar T C",
        "Scott S A",
        "Stingl J C",
        "Klein T E",
        "Caudle K E",
        "Gaedigk A",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2015,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"
    }
  ],
  "version": "2024-02-29-20-19"
}